According to the pharmaceutical and biotech industry on the 8th, G2GBIO, Inc. is proceeding with follow-up procedures for the long-acting injectable formulation development agreements signed with Boehringer twice last year. The company announced at an investor briefing last April that it had completed formulation development and that Boehringer was conducting large-animal evaluations. Further discussions are expected in the second half of the year based on those results.
Some observers have speculated that the results of the large-animal evaluations or the candidate compounds may be disclosed in the second half of the year. However, it is understood that there are no plans to publicly release the joint research data itself. A G2GBIO, Inc. official stated, “Just because we receive the results of the joint research does not mean they will be disclosed to the public,” adding, “We will discuss the next steps based on the results, and if the subsequent decisions fall under disclosure requirements, we will announce them through a public disclosure.”
Although there were predictions that the results would be announced after the joint research concludes this October, no specific end date was stipulated in the contract. Since both agreements were signed before G2GBIO, Inc.’s listing on the KOSDAQ market, the contract terms and specific conditions were not disclosed separately. Rather than waiting for the announcement of research results, whether Boehringer actually expands the collaboration will serve as the benchmark for assessing G2GBIO, Inc.’s performance in the second half of this year.
The collaboration between the two companies began in January of last year. In January of last year, G2GBIO, Inc. signed a formulation development agreement to apply its proprietary drug delivery platform, “InnoLAMP,” to a proprietary peptide held by Boehringer Ingelheim. Under this arrangement, Boehringer Ingelheim provides the candidate compound and related information, while G2GBIO, Inc. designs an injectable formulation capable of maintaining long-term drug efficacy.
About six months later, in July of the same year, an additional formulation development agreement followed. The second agreement did not involve adding a separate candidate compound but rather applied different Target Product Characteristics (TPP) to the same product as the first agreement. TPP refers to the target performance of the drug being developed, such as dosing frequency, dosage, drug release rate, and injection volume.
G2GBIO, Inc. explained that the additional contract was driven by the confirmation of InnoLamp’s efficacy, differentiation, and scalability during the first formulation development process. Since Boehringer Ingelheim did not stop at testing a single formulation but also entrusted G2GBIO, Inc. with developing a formulation applying different product conditions to the same product, this is interpreted as an evaluation of options for actual commercialization that goes beyond mere feasibility.
InnoLamp is a platform that encapsulates drugs in biodegradable microparticles to enable their gradual release within the body. G2GBIO, Inc. explains that by loading more than 40% of the peptide drug into the microparticles, it can suppress excessive drug release early in the administration period.
In the large-animal studies being conducted by Boehringer Ingelheim, the primary focus is expected to be on verifying whether the formulation designed by G2GBIO, Inc. maintains an appropriate drug concentration over the target period. For long-acting injectables, it is crucial to reduce “initial over-release”—where the drug is released all at once immediately after administration—while maintaining a consistent concentration throughout the entire administration period. Large-animal studies are considered a key step in assessing pharmacokinetic characteristics and commercial viability before administering the drug to humans.
If the evaluation results meet the target criteria, the scope of collaboration between the two companies could expand. The first options being discussed include further optimizing the formulation of the same candidate compound or proceeding with follow-up validation steps such as the production of clinical samples and technical due diligence. There is also the possibility that this could lead to a licensing agreement granting Boehringer the right to apply InoLamp to the candidate compound, or to an agreement for the development of additional formulations targeting a new TPP. The market, including the securities industry, is anticipating the signing of a definitive agreement in the second half of this year.
Of course, the fact that the candidate’s name and indications have not been disclosed makes it difficult to predict the outcome. Since the research results have not been made public and the candidate’s name and indications remain confidential, the success of this project can only be indirectly confirmed through subsequent agreements.
Since the substance provided by Boehringer is a new peptide and the company’s clinical-stage peptide pipeline is focused on cardiovascular, renal, and metabolic diseases—including obesity—it is merely speculated that the candidate is related to these areas. Boehringer is developing the GLP-1/glucagon dual agonist “Servodutide” and the GLP-1/GIP/NPY2 triple agonist “BI 3034701,” among others.
Nevertheless, if a follow-up agreement with Boehringer is finalized, it could serve as an opportunity to demonstrate that Inolamp is a platform applicable not only to specific in-house pipelines but also to new drug candidates held by global pharmaceutical companies.
A pharmaceutical and biotech industry official stated, “The fact that an overseas pharmaceutical company provided its own candidate compounds and evaluated formulations tailored to multiple target product characteristics can be viewed as a more advanced stage than a simple technology introduction,” adding, “Since the results of the joint research have not been disclosed separately, we need to monitor whether an announcement regarding a follow-up agreement with Boehringer will be made in the second half of the year.”
